Your browser doesn't support javascript.
loading
Perspective on Management of Low-Dose Computed Tomography Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening. From the International Association for the Study of Lung Cancer Early Detection and Screening Committee.
Henschke, Claudia; Huber, Rudolf; Jiang, Long; Yang, Dawei; Cavic, Milena; Schmidt, Heidi; Kazerooni, Ella; Zulueta, Javier J; Sales Dos Santos, Ricardo; Ventura, Luigi.
Afiliación
  • Henschke C; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: cihenschke@gmail.com.
  • Huber R; Division of Respiratory Medicine and Thoracic Oncology, Department of Medicine, University of Munich - Campus Innenstadt, Ziemssenstrabe, Munich, Germany.
  • Jiang L; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Yang D; Department of Pulmonary Medicine and Critical Care, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Cavic M; Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
  • Schmidt H; Department of Medical Imaging, Toronto General Hospital, Toronto, Canada.
  • Kazerooni E; Division of Cardiothoracic Radiology and Internal Medicine, University of Michigan Medical School, Frankel Cardiovascular Center, Ann Arbor, Michigan.
  • Zulueta JJ; Department of Medicine, Mount Sinai Morningside, New York, New York.
  • Sales Dos Santos R; Department of Minimally Invasive Thoracic and Robotic Surgery, Albert Einstein Israeli Hospital, Sao Paulo, Brazil.
  • Ventura L; Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.
J Thorac Oncol ; 19(4): 565-580, 2024 Apr.
Article en En | MEDLINE | ID: mdl-37979778
ABSTRACT
Lung cancer screening using low-dose computed tomography (LDCT) carefully implemented has been found to reduce deaths from lung cancer. Optimal management starts with selection of eligibility criteria, counseling of screenees, smoking cessation, selection of the regimen of screening which specifies the imaging protocol, and workup of LDCT findings. Coordination of clinical, radiologic, and interventional teams and ultimately treatment of diagnosed lung cancers under screening determine the benefit of LDCT screening. Ethical considerations of who should be eligible for LDCT screening programs are important to provide the benefit to as many people at risk of lung cancer as possible. Unanticipated diseases identified on LDCT may offer important benefits through early detection of leading global causes of death, such as cardiovascular diseases and chronic obstructive pulmonary disease, as the latter may result from conditions such as emphysema and bronchiectasis, which can be identified early on LDCT. This report identifies the key components of the regimen of LDCT screening for lung cancer which include the need for a management system to provide data for continuous updating of the regimen and provides quality assurance assessment of actual screenings. Multidisciplinary clinical management is needed to maximize the benefit of early detection, diagnosis, and treatment of lung cancer. Different regimens have been evolving throughout the world as the resources and needs may be different, for countries with limited resources. Sharing of results, further knowledge, and incorporation of technologic advances will continue to accelerate worldwide improvements in the diagnostic and treatment approaches.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Cese del Hábito de Fumar / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2024 Tipo del documento: Article